![](https://img.mlo-online.com/files/base/ebm/mlo/image/2025/02/67a0de8c1b51bcafce4aec67-dreamstime_xxl_93061568.png?auto=format,compress&fit=fill&fill=blur&w=1200&h=630)
Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast ...
Roche announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody to identify patients with HR-positive, HER2-ultralow metastatic breast cancer who may …